Dashboard
Manage Tickers

BIIBBIOGEN INC.

Nasdaq biogen.com


$ 205.46 $ -0.57 (-0.28 %)    

Tuesday, 20-Aug-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.15 $ -1.15 (-0.24 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.51 (-0.09 %)
TLT $ 98.68 $ 0.38 (0.39 %)
GLD $ 232.46 $ -1.26 (-0.54 %)
$ 205.49
$ 205.75
$ 205.32 x 100
-- x --
$ 205.32 - $ 206.98
$ 189.44 - $ 270.50
625,025
na
29.98B
$ 0.69
$ 25.88
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 04-24-2024 03-31-2024 10-Q
3 02-14-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 07-25-2023 06-30-2023 10-Q
6 04-25-2023 03-31-2023 10-Q
7 02-15-2023 12-31-2022 10-K
8 10-25-2022 09-30-2022 10-Q
9 07-20-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-03-2022 12-31-2021 10-K
12 10-20-2021 09-30-2021 10-Q
13 07-22-2021 06-30-2021 10-Q
14 04-22-2021 03-31-2021 10-Q
15 02-03-2021 12-31-2020 10-K
16 10-21-2020 09-30-2020 10-Q
17 07-22-2020 06-30-2020 10-Q
18 04-23-2020 03-31-2020 10-Q
19 02-06-2020 12-31-2019 10-K
20 10-22-2019 09-30-2019 10-Q
21 07-24-2019 06-30-2019 10-Q
22 04-24-2019 03-31-2019 10-Q
23 02-06-2019 12-31-2018 10-K
24 10-23-2018 09-30-2018 10-Q
25 07-24-2018 06-30-2018 10-Q
26 04-24-2018 03-31-2018 10-Q
27 02-01-2018 12-31-2017 10-K
28 10-24-2017 09-30-2017 10-Q
29 07-25-2017 06-30-2017 10-Q
30 04-25-2017 03-31-2017 10-Q
31 02-02-2017 12-31-2016 10-K
32 10-26-2016 09-30-2016 10-Q
33 07-21-2016 06-30-2016 10-Q
34 04-21-2016 03-31-2016 10-Q
35 02-03-2016 12-31-2015 10-K
36 10-21-2015 09-30-2015 10-Q
37 07-24-2015 06-30-2015 10-Q
38 04-24-2015 03-31-2015 10-Q
39 02-04-2015 12-31-2014 10-K
40 10-22-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cracking-the-code-understanding-analyst-reviews-for-biogen
Cracking The Code: Understanding Analyst R...
08/19/2024 13:00:41

needham-reiterates-buy-on-biogen-maintains-285-price-target
Needham Reiterates Buy on Biogen, Maintain...
08/19/2024 09:31:20

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $285 price target.

how-is-the-market-feeling-about-biogen
How Is The Market Feeling About Biogen?
08/09/2024 19:45:24

mizuho-maintains-outperform-on-biogen-lowers-price-target-to-251
Mizuho Maintains Outperform on Biogen, Low...
08/06/2024 11:19:51

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $277 to $251.

truist-securities-reiterates-buy-on-biogen-lowers-price-target-to-302
Truist Securities Reiterates Buy on Biogen...
08/05/2024 13:43:51

Truist Securities analyst Srikripa Devarakonda reiterates Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $...

needham-maintains-buy-on-biogen-lowers-price-target-to-285
Needham Maintains Buy on Biogen, Lowers Pr...
08/05/2024 10:12:38

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $288 to $285.

rbc-capital-maintains-outperform-on-biogen-raises-price-target-to-292
RBC Capital Maintains Outperform on Biogen...
08/02/2024 19:46:44

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $282 to...

wells-fargo-maintains-equal-weight-on-biogen-lowers-price-target-to-225
Wells Fargo Maintains Equal-Weight on Biog...
08/02/2024 18:28:35

Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $240 to...

scotiabank-maintains-sector-outperform-on-biogen-lowers-price-target-to-244
Scotiabank Maintains Sector Outperform on ...
08/02/2024 16:31:15

Scotiabank analyst George Farmer maintains Biogen (NASDAQ:BIIB) with a Sector Outperform and lowers the price target from $2...

barclays-maintains-equal-weight-on-biogen-lowers-price-target-to-190
Barclays Maintains Equal-Weight on Biogen,...
08/02/2024 14:31:57

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $200 to $190.

wedbush-maintains-neutral-on-biogen-lowers-price-target-to-210
Wedbush Maintains Neutral on Biogen, Lower...
08/02/2024 13:47:57

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $215 to $210.

us-stocks-tumble-on-economic-geopolitical-concerns-small-caps-chipmakers-sink-meta-rallies-whats-driving-markets-thursday
US Stocks Tumble On Economic, Geopolitical...
08/01/2024 17:11:53

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively imp...

biogen-q2-earnings-beats-consensus-lifts-2024-profit-forecast-as-new-drug-launches-expected-to-offset-decline-in-multiple-sclerosis-med-sales
Biogen Q2 Earnings: Beats Consensus, Lifts...
08/01/2024 15:23:42

Biogen reported Q2 adjusted EPS of $5.28, surpassing the $4.03 consensus. Sales were $2.47 billion, narrowly beating the $2.38 ...

biogen-exec-says-believe-ema-concerns-for-alzheimers-drug-are-addressable-with-the-available-data
Biogen Exec Says Believe Ema Concerns For ...
08/01/2024 13:23:12

-Conf. Call

needham-reiterates-buy-on-biogen-maintains-288-price-target
Needham Reiterates Buy on Biogen, Maintain...
08/01/2024 12:40:31

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $288 price target.

wall-street-looks-to-ride-on-earnings-cheer-as-meta-q2-impresses-investors-analyst-says-economic-data-stock-performances-suggest-republican-win-in-november
Wall Street Looks To Ride On Earnings Chee...
08/01/2024 11:35:52

After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. Th...

biogen-expects-2024-adjusted-eps-of-1575-1625-versus-prior-guidance-of-1500-1600-and-consensus-of-1558
Biogen Expects 2024 Adjusted EPS Of $15.75...
08/01/2024 11:00:59

Biogen now expects total revenue to decline by a low-single digit percentage (previously low to mid-single percentage), with co...

biogen-shares-are-trading-higher-following-better-than-expected-q2-financial-results
Biogen shares are trading higher following...
08/01/2024 10:59:47

biogen-q2-2024-adj-eps-528-beats-403-estimate-sales-2465b-beat-2382b-estimate
Biogen Q2 2024 Adj. EPS $5.28 Beats $4.03 ...
08/01/2024 10:58:44

Core News & Articles
Alcyone Therapeutics Announces Continued E...
07/31/2024 13:08:46

Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therape...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION